Showing 8031-8040 of 8647 results for "".
- Microstent Reduces Post-Cataract Surgery Intraocular Pressure in Glaucoma Patientshttps://modernod.com/news/microstent-reduces-post-cataract-surgery-intraocular-pressure-in-glaucoma-patients/2477293/Microstent implantation in Schlemm’s canal reduces early postoperative IOP following cataract surgery in patients with mild or moderate glaucoma, according to findings from the HORIZON study of the Hydrus microstent, according to a Reuters
- Ocular Therapeutix Presents Data Demonstrating a Reduction in IOP in Patients Treated with OTX-TIChttps://modernod.com/news/ocular-therapeutix-presents-data-demonstrating-a-reduction-in-iop-in-patients-treated-with-otx-tic/2477290/Ocular Therapeutix presented data on OTX-TIC, a long acting travoprost intracameral implant for the treatment of patients with primary open angle glaucoma or ocular hypertension. Data from this phase 1 clinical trial demonstrated a clinically-meaningful reduction in IOP for up to 18 months in the
- Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Deviceshttps://modernod.com/news/santen-and-verily-establish-joint-venture-to-develop-and-commercialize-unique-ophthalmic-devices/2477285/Santen Pharmaceutical and Alphabet subsidiary Verily announced the establishment of a joint venture focused on applying microelectronics and scalable digital technologies to ophthalmology. The new joint venture is driven by a mission to improve eye health for people everywhere, starting by
- Oxurion Presentation of Positive Topline Data from a Phase 1 Study Evaluating THR-687 for the Treatment of DMEhttps://modernod.com/news/oxurion-presentation-of-positive-topline-data-from-a-phase-1-study-evaluating-thr-687-for-the-treatment-of-dme/2477284/Oxurion NV announced that further positive topline data from a phase 1 study with THR-687, a novel, potent, pan-RGD integrin antagonist for the treatment of diabetic macular edema (DME), was presented by Arshad Khanani, MD, MA, Director of Clinical Research at Sierra Eye Associates, Reno, Nevada,
- Nicox to Present NCX 470 Phase 2 Results at Glaucoma 360 New Horizons Forumhttps://modernod.com/news/nicox-to-present-ncx-470-phase-2-results-at-glaucoma-360-new-horizons-forum/2477281/Nicox SA today announced that Tomas Navratil, PhD, Executive Vice President, Head of R&D of Nicox group, and General Manager of Nicox Ophthalmics, Inc, will present results from the NCX 470 Dolomites phase 2 clinical trial in the session “New Horizons in Pharmaceuticals” at the Glaucoma 360 N
- ProQR Therapeutics Teams Up With Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker Program for People With Inherited Retinal Diseaseshttps://modernod.com/news/proqr-therapeutics-teams-up-with-foundation-fighting-blindness-and-blueprint-genetics-to-support-the-my-retina-tracker-program-for-people-with-inherited-retinal-diseases/2477280/ProQR Therapeutics, a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, announced its participation in the Foundation Fighting Blindness My Retina Tracker Program, a collaborative, open-access program run by Blueprint Geneti
- Marinosolv Technology Successfully Used in Preclinical Study of Neurotrophic Keratopathyhttps://modernod.com/news/marinosolv-technology-successfully-used-in-preclinical-study-of-neurotrophic-keratopathy/2477279/Marinomed Biotech, a globally active biopharmaceutical company with headquarters in Vienna, and the renowned University of Utah have published scientific investigations that provide initial evidence for further significant benefits of the innovative Marinosolv platform in the field of corneal eye
- Nicox Receives Formulation Patent Extending NCX 470 US Patent Coverage to 2039https://modernod.com/news/nicox-receives-formulation-patent-extending-ncx-470-us-patent-coverage-to-2039/2477270/Nicox has received approval from the U.S. Patent and Trademark Office of a formulation patent for NCX 470, extending the U.S. patent coverage to 2039. NCX 470, a novel second gener
- ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421ahttps://modernod.com/news/proqr-receives-rare-pediatric-disease-designation-from-fda-for-qr-421a/2477267/ProQR Therapeutics announced that it received Rare Pediatric Disease (RPD) designation from the FDA for QR-421a for the treatment of patients with retinitis pigmentosa caused by mutations in exon 13 of the USH2A gene. QR-421a is a first-in-class investigational RNA-based oligonucl
- ForwardVue Pharma CEO: “Short Path to the Clinic” for Retinal Disease Treatmenthttps://modernod.com/news/forwardvue-pharma-ceo-short-path-to-the-clinic-for-retinal-disease-treatment/2477263/In an interview with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco, ForwardVue Pharmaceuticals CEO Alan Franklin, MD, PhD, who is an ophthalmologist, said the company’s lead molecule aims to treat retinal neovascular disease.